Clinical Trial

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 20, 2021 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2019-10-22; most recent amendment 2021-07-18.
Status change: Not Yet Recruiting → Recruiting 2021-07-18
Trial Details
NCT Number NCT04136782
Lead Sponsor Shengjing Hospital
Conditions Breast Cancer
Enrollment 110 participants
Start Date 2021-07-19
Primary Completion 2025-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2021-07-20